Combretastatin

DB12596InvestigationalSmall molecule

Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Chemical structure of Combretastatin
Mechanism
Curator reviewed
Formula / weight
C18H22O6 · 334.368 g/mol (avg)
Code names
NSC-348103

Resolves to

Compound
UNII7O62J06F18CAS82855-09-2ChEMBLCHEMBL246600PubChem9895264
Structure
InChIKeyLGZKGOGODCLQHG-CYBMUJFWSA-NSMILESCOC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Combretastatin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In